SOBI: Business ManRare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the company’s new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of … more ➔
uniQure: Doctor’s ordersDutch gene therapy developer uniQure has appointed Steven l. Zelenkofske as its Chief Medical Officer. more ➔
Recipharm: Strategic appointmentContract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK … more ➔
Virbac: Managing global operationsFrench vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial … more ➔
Luminary in vaccine researchJan Holmgren, developer of the first effective oral cholera vaccine, has been awarded the 2017 Sabin Gold Medal for his pioneering contributions to oral vaccine research and mucosal immunology, and his … more ➔
Pharmalink: Launching into Phase IIIPharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical … more ➔
Metrion Biosciences: Developing the busine...Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of … more ➔
Gyros Protein Technologies: European Marke...Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales. more ➔
GenSight Biologics: Progressing the ophtha...Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina … more ➔
Kymab: Track record in clinical developmen...Antibody developer Kymab Ltd has instated Sonia Quaratino as its first Chief Medical Officer. She will manage the clinical development of the Group’s expanding therapeutic antibody portfolio. more ➔
